BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (41)
2024
2023
-
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Blood, Vol. 141, Núm. 2, pp. 156-167
-
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773
-
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1058-1069
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
2021
-
Impact of the COVID-19 pandemic on the care of cancer patients in Spain
ESMO open, Vol. 6, Núm. 3, pp. 100157
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC
Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
European Journal of Haematology, Vol. 105, Núm. 2, pp. 138-147
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Blood Cancer Journal, Vol. 10, Núm. 2
-
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018
2019
-
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759